×ðÁú¹Ù·½

English

×ðÁú¹Ù·½ÉúÎïѪ˨ËÄÏî | ΪDICÔçÆÚÕï¶ÏÌṩÓÐÁ¦Ö§³Ö

Ðû²¼ÓÚ£º2024-12-20

ÎÄÕÂȪԴ£º[ÖÐÎÄ]×ðÁú¹Ù·½ÉúÎï




01

DIC¸ÅÊö


ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪ£¨disseminated intravascular coagulation£¬£¬£¬ £¬£¬ £¬DIC£©ÊÇÔÚÐí¶à¼²²¡»ù´¡ÉÏ£¬£¬£¬ £¬£¬ £¬Ö²¡ÒòËØËðÉË΢Ѫ¹Üϵͳ£¬£¬£¬ £¬£¬ £¬µ¼ÖÂÄýѪ»î»¯£¬£¬£¬ £¬£¬ £¬È«Éí΢Ѫ¹ÜѪ˨Ðγɡ¢ÄýѪÒò×Ó´ó×ÚÏûºÄ²¢¼Ì·¢ÏËÈÜ¿º½ø£¬£¬£¬ £¬£¬ £¬ÒýÆðÒÔ³öѪ¼°Î¢Ñ­»·Ë¥½ßÎªÌØÕ÷µÄÁÙ´²×ÛºÏÕ÷¡£¡£¡£¡£¡£ ¡£¡£


DIC²»ÊÇÒ»¸ö×ÔÁ¦µÄ¼²²¡£¬£¬£¬ £¬£¬ £¬¶øÊÇÖڶ༲²¡ÖØ´ó²¡ÀíÀú³ÌÖеÄÖÐÐÄ»·½Ú£¬£¬£¬ £¬£¬ £¬Æä»ù´¡¼²²¡»òÓÕÒò°üÀ¨£ºÑÏÖØÑ¬È¾£¨Å§¶¾Ö¢µÈ£©¡¢¶ñÐÔÖ×Áö¡¢²¡Àí²ú¿Æ¡¢Íâ¿ÆÊÖÊõ¼°ÍâÉËÖж¾ºÍÃâÒßËðÉ˵È£¬£¬£¬ £¬£¬ £¬ÆäÖÐѬȾÊÇ×î³£¼ûµÄÔµ¹ÊÔ­ÓÉ¡£¡£¡£¡£¡£ ¡£¡£


DIC¼²²¡Ìص㣺Æð²¡ÒþÄ䣬£¬£¬ £¬£¬ £¬ÔçÆÚ¿ÉÎÞÏÔÖøÌØÕ÷£¬£¬£¬ £¬£¬ £¬¾ßÓÐÏ£Íû¿ì¡¢Ô¤ºó²î¡¢éæÃüÂʸߵÈ¡£¡£¡£¡£¡£ ¡£¡£


DICʹ»¼Õ߯÷¹ÙË¥½ßºÍéæÃüµÄΣÏÕÐÔÏÔ×ÅÔöÌí£¬£¬£¬ £¬£¬ £¬ÔÚ²î±ð±¨µÀÖУ¬£¬£¬ £¬£¬ £¬DIC»¼Õß²¡ËÀÂʸߴï31%~86%£¬£¬£¬ £¬£¬ £¬Òò´ËÓÐѧÕß°ÑDICг³ÆÎª¡°Death Is Coming¡±¡£¡£¡£¡£¡£ ¡£¡£ÓÉÓÚDIC»ù´¡¼²²¡ºÍÁÙ´²ÌåÏÖ¶àÑù»¯¡¢·ÖÆÚÖØ´ó£¬£¬£¬ £¬£¬ £¬Ê¹ÆäÈÝÒ×ÓëÆäËûÒýÆð³öÄýѪÒì³£¼²²¡Ïà»ìÏý£¬£¬£¬ £¬£¬ £¬¼«Ò×±»ºöÊÓ£¬£¬£¬ £¬£¬ £¬ÑÏÖØÓ°Ï컼ÕßÔ¤ºó£¬£¬£¬ £¬£¬ £¬Òò´ËDICµÄÔçÆÚÕï¶ÏÊÇDICÕïÖεÄÒªº¦¡£¡£¡£¡£¡£ ¡£¡£





×ðÁú¹Ù·½ÉúÎïѪ˨ËÄÏîÒÑÈ¡µÃ×¢²áÖ¤£¬£¬£¬ £¬£¬ £¬ÔÚDICÔçÆÚÕï¶Ï¿ÉÒÔÌṩÓÐÁ¦Ö§³Ö£¡



02

DICÕï¶Ï±ê×¼µÄÏÖ×´


DICµÄ±¬·¢ÆøÖÆÖش󣬣¬£¬ £¬£¬ £¬Ö²¡ÒòËØ²î±ð£¬£¬£¬ £¬£¬ £¬Æä¶ÔÓ¦µÄ²¡ÀíÐÄÀí»úÖÆ¼°ÁÙ´²ÌصãÒ²±£´æºÜ´ó²î±ð£¬£¬£¬ £¬£¬ £¬DICµÄÕï¶ÏÊÇÏÖÔÚÁÙ´²±£´æµÄÒ»¸öÄÑÌâ¡£¡£¡£¡£¡£ ¡£¡£



ÏÖÔÚÖ¸ÄÏÍÆ¼öʹÓùú¼ÊѪ˨ÓëֹѪѧ»á±ê×¼£¨ISTH-DIC£©¡¢ÖйúDICÕï¶Ï»ý·Öϵͳ£¨CDSS-DIC£©ÆÀ·ÖϵͳÕï¶ÏDIC¡£¡£¡£¡£¡£ ¡£¡£±ðµÄ£¬£¬£¬ £¬£¬ £¬2019ÄêISTH¹«²¼ÁËŧ¶¾Ö¢ÐÔÄýѪ²¡(sepsis-induced coagulopathy£¬£¬£¬ £¬£¬ £¬SIC)Õï¶Ï±ê×¼£¬£¬£¬ £¬£¬ £¬ËäÈ»ÏÖ´æÐí¶àDICÕï¶Ï±ê×¼£¬£¬£¬ £¬£¬ £¬¿ÉÊǸ÷×Ô±£´æÒ»¶¨µÄ¾ÖÏÞÐÔ£¬£¬£¬ £¬£¬ £¬¶ÔDICÔçÆÚÕï¶Ï¼°DICÔ¤ºóÅжÏѸËٶȺÍÌØÒì¶È¾ùÓдýÌá¸ß£¬£¬£¬ £¬£¬ £¬ÓÈÆäÊǶÔéæÃüµÄÅжÏÒÔ¼°pre-DICµÄÕï¶Ï£¬£¬£¬ £¬£¬ £¬ÏÖÔÚÈÔȱ·¦DICÕï¶ÏµÄ½ð±ê×¼¡£¡£¡£¡£¡£ ¡£¡£Òò´ËÁÙ´²ÉÏÐèÒªÒÀÍÐеÄÄýѪ·Ö×Ó±ê¼ÇÎィÉèЧÄܸü¸ßµÄDIC¾«×¼Õï¶Ïϵͳ¡£¡£¡£¡£¡£ ¡£¡£½üÄêÑо¿Ï£Íû¿ì¡¢ÁÙ´²Ö¸µ¼ÒâÒåÇ¿µÄÐÂÐÍÄýѪ·Ö×Ó±ê¼ÇÎï°üÀ¨ÄýѪø-¿¹ÄýѪø¸´ºÏÎï(thrombin-antithrombin compex£¬£¬£¬ £¬£¬ £¬TAT)¡¢ÏËÈÜø-¿¹ÏËÈÜø¸´ºÏÎï(plasmin antiplasmincomplex£¬£¬£¬ £¬£¬ £¬PIC)¡¢×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï-ÏËÈÜøԭ¼¤»îÒÖÖÆÎï-1¸´ºÏÎï(tissue plasminogen activator-plasminogen activator inhibitor-l complex£¬£¬£¬ £¬£¬ £¬t-PAIC)¼°ÑªË¨µ÷ÀíÂѰ×(thrombomodulin£¬£¬£¬ £¬£¬ £¬TM)¡£¡£¡£¡£¡£ ¡£¡£



03
 

ÐÂѪ˨ËÄÏîÖúÁ¦DICÔçÕïÔçÖÎ


2017Ä꣬£¬£¬ £¬£¬ £¬¡¶ÖлªÑªÒºÑ§ÔÓÖ¾¡·½ÒÏþµÄ¡¶ÃÖÂþÐÔѪ¹ÜÄÚÄýѪÕï¶ÏÖйúר¼Ò¹²Ê¶¡·TAT¿ÉÓÃÓÚDICÔçÆÚÕï¶Ï¡£¡£¡£¡£¡£ ¡£¡£Í¬Ä꣬£¬£¬ £¬£¬ £¬ÈÕ±¾ÑªË¨ÓëֹѪѧ»á£¨JSTH£©DICÕï¶Ï±ê×¼ÖÐÒýÈëÁËTAT¼ì²â¡£¡£¡£¡£¡£ ¡£¡£2020Ä꣬£¬£¬ £¬£¬ £¬¡¶Öлª¼±ÕïҽѧÔÓÖ¾¡·½ÒÏþµÄ¡¶¼±ÐÔ³öѪÐÔÄýѪ¹¦Ð§Õϰ­ÕïÖÎר¼Ò¹²Ê¶¡·ÖÐÖ¸³ö£¬£¬£¬ £¬£¬ £¬ÑªË¨·Ö×Ó±ê¼ÇÎ£¬£¬ £¬£¬ £¬TAT¿ÉÔçÆÚÕ¹ÍûѪ˨Ðγɺ͸´·¢Î£º¦£¬£¬£¬ £¬£¬ £¬ÔçÆÚÕ¹ÍûDICΣº¦£»£»£»£» £»£»PIC¿ÉÓÃÓÚDIC·ÖÐÍ¡¢ÈÜ˨ÖÎÁÆ£»£»£»£» £»£»tPAIC¶ÔDIC¡¢ÐÂÎÅÂöѪ˨¾ùÓÐÌáÐÑ×÷Ó㻣»£»£» £»£»TM¿ÉÌáÐÑѪ¹ÜÄÚÆ¤ËðÉ˿ɼûÓÚŧ¶¾Ö¢¡¢Éö¹¦Ð§ÊÜËðºÍ¼±ÐÔ·ÎËðÉ˵È¡£¡£¡£¡£¡£ ¡£¡£¹ØÓÚÁÙ´²ÇéÐÎÖØ´óµÄ»¼Õߣ¬£¬£¬ £¬£¬ £¬ÍƼöʹÓÃTAT¡¢PIC¡¢tPAIC¡¢TM×÷ÔçÆÚÆÀ¹À¡£¡£¡£¡£¡£ ¡£¡£


1

TAT  ÄýѪø-¿¹ÄýѪø¸´ºÏÎï

ÌåÄÚÄýѪøÐγɺ󣬣¬£¬ £¬£¬ £¬²¿·ÖѸËÙÓ뿹ÄýѪø(antithrombin£¬£¬£¬ £¬£¬ £¬AT)ÍŽáÐγÉTAT£¬£¬£¬ £¬£¬ £¬¸ÃÖ¸±êÊÇ·´Ó¦ÄýѪøÌìÉúµÄ·Ö×Ó±ê¼ÇÎ£¬£¬ £¬£¬ £¬¿ÉѸËٵط´Ó¦ÄýѪϵͳµÄ¼¤»îˮƽ£¬£¬£¬ £¬£¬ £¬Ö±½Ó·´Ó¦ÄýѪϵͳÆô¶¯¡£¡£¡£¡£¡£ ¡£¡£ÄýѪøÔÚѪҺÖаëË¥ÆÚ½öÊýÃ룬£¬£¬ £¬£¬ £¬Ö±½Ó²â¶¨ÄÑÌâ¡£¡£¡£¡£¡£ ¡£¡£TATµÄѪ½¬°ëË¥ÆÚΪ3~15 min£¬£¬£¬ £¬£¬ £¬¿ÉÒÔÖ±½Ó²â¶¨£¬£¬£¬ £¬£¬ £¬TATѪ½¬Õý³£ÖµÎª<4 ng/mL£¬£¬£¬ £¬£¬ £¬TAT>4 ng/mL£¬£¬£¬ £¬£¬ £¬ÌáÐÑÄýѪøºÏ³ÉÔö¶à¡£¡£¡£¡£¡£ ¡£¡£TATÉý¸ß¿ÉÔçÆÚÕ¹ÍûѪ˨Ðγɺ͸´·¢Î£º¦¡¢ÔçÆÚÕ¹ÍûDICΣº¦¡£¡£¡£¡£¡£ ¡£¡£

2

PIC  ÏËÈÜø-¿¹ÏËÈÜø¸´ºÏÎï

PICÊÇÏËÈÜøÓëÒÖÖÆÒò×Ó¦Á2¿¹ÏËÈÜøÒÔ1:1ÍŽáÐγɵĸ´ºÏÎ£¬£¬ £¬£¬ £¬ÊÇÖ±½Ó·´Ó¦ÏËÈÜϵͳ¼¤»îˮƽµÄÉúÎï±ê¼ÇÎï¡£¡£¡£¡£¡£ ¡£¡£PICѪ½¬°ëË¥ÆÚÔ¼6h£¬£¬£¬ £¬£¬ £¬¿ÉÖ±½Ó²â¶¨£¬£¬£¬ £¬£¬ £¬Ñª½¬Õý³£ÖµÎª<0.8¦Ìg/mL£¬£¬£¬ £¬£¬ £¬PIC>0.8 ¦Ìg/mL³£ÌáÐÑÏËÈÜϵͳ¼¤»î¡£¡£¡£¡£¡£ ¡£¡£ÏËÈܼ¤»îˮƽÒòDIC»ù´¡¼²²¡²î±ð¶øÓÐËù²î±ð£¬£¬£¬ £¬£¬ £¬ÇÒÓëDIC·ÖÐÍÇ×½üÏà¹Ø£¬£¬£¬ £¬£¬ £¬¿ÉÓÃÓÚÔçÆÚÕ¹Íû¸ßÄý״̬£¬£¬£¬ £¬£¬ £¬Ò²¿ÉÓÃÓÚÈÜ˨ÖÎÁƼà²â¡£¡£¡£¡£¡£ ¡£¡£

3

t-PAIC  ×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï-ÏËÈÜøԭ¼¤»îÒÖÖÆÎï-1¸´ºÏÎï

Ѫ¹ÜÄÚÆ¤Ï¸°ûËðÉËʱ£¬£¬£¬ £¬£¬ £¬×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï¼°ÏËÈÜøԭ¼¤»îÒÖÖÆÎï-1ͬʱÊͷŵ½ÑªÒºÖУ¬£¬£¬ £¬£¬ £¬1:1ÍŽáÐγÉtPAIC£¬£¬£¬ £¬£¬ £¬tPAICÄܹ»·´Ó¦ÄÚÆ¤Ï¸°ûµÄËðÉË£¬£¬£¬ £¬£¬ £¬ÊÇÏËÈÜϵͳ¼¤»îµÄ·Ö×Ó±ê¼ÇÎ£¬£¬ £¬£¬ £¬ÄÐÐÔѪ½¬Õý³£Öµ<17.0 ng/mL£¬£¬£¬ £¬£¬ £¬Å®ÐÔ<10.5 ng/mL¡£¡£¡£¡£¡£ ¡£¡£tPAIC ¶ÔDIC¡¢ÐÂÎÅÂöѪ˨¾ùÓÐÌáÐÑ×÷Ó㬣¬£¬ £¬£¬ £¬ÊǾ²ÂöѪ˨˨ÈûÖ¢(veinthromboembolism,VTE)¼°ÐĹ£µÄΣº¦Ö¸±ê£¬£¬£¬ £¬£¬ £¬±ðµÄ¸ÃÖ¸±ê¶ÔDICÕï¶Ï¾ßÓÐÖ÷Òª¼ÛÖµ£¬£¬£¬ £¬£¬ £¬Ñª½¬Ë®Æ½Éý¸ßÌáÐÑDIC¿ÉÄÜѪ¹ÜÄÚÆ¤Ï¸°ûËðÉË¡¢ÑªË¨ÐγÉ¡£¡£¡£¡£¡£ ¡£¡£

4

TM  Ѫ˨µ÷ÀíÂѰ×

TMΪÄÚÆ¤Ï¸°ûÍâòµÄÄýѪøÊÜÌ壬£¬£¬ £¬£¬ £¬ÒÖÖÆÄýѪøµÄ»îÐÔ£¬£¬£¬ £¬£¬ £¬ÔöÇ¿ÂѰ×C»î»¯ÐÔÄÜ£¬£¬£¬ £¬£¬ £¬Ñª½¬TMÕý³£ÖµÎª3.8~13.3 TU/mL¡£¡£¡£¡£¡£ ¡£¡£µ±ÄÚÆ¤Ï¸°ûÊÜËð»ò¹¦Ð§Õϰ­Ê±£¬£¬£¬ £¬£¬ £¬TM±í´ï½µµÍ£¬£¬£¬ £¬£¬ £¬²¿·ÖTM±»ÂѰ×øˮ½âÖÁѪ½¬ÖС£¡£¡£¡£¡£ ¡£¡£Òò´Ë£¬£¬£¬ £¬£¬ £¬TMÊÇÄÚÆ¤Ï¸°ûÊÜËðµÄ±ê¼ÇÎï¡£¡£¡£¡£¡£ ¡£¡£TMÉý¸ßÌáÐÑѪ¹ÜÄÚÆ¤ËðÉË£¬£¬£¬ £¬£¬ £¬¿É¼ûÓÚŧ¶¾Ö¢¡¢Éö¹¦Ð§ÊÜËð¡¢¼±ÐÔ·ÎËðÉ˵È¡£¡£¡£¡£¡£ ¡£¡£


ÐÂѪ˨ËÄÏîÍŽá¼ì²â¶ÔÕï¶ÏDICµÄ¼ÛÖµ¸ü¸ß


Ò»Ïî¶àÖÐÐÄǰհÐÔÊÓ²ìÑо¿Åú×¢TAT¡¢PIC¡¢tPAICºÍsTMÔÚ²î±ð»ù´¡¼²²¡µÄDIC»¼ÕßÖÐÌåÏÖ³öÓÅÒìµÄÕï¶ÏÐÔÄܺÍÔ¤ºó¼ÛÖµ£¬£¬£¬ £¬£¬ £¬TAT¡¢tPAICºÍsTMÔÚpre-DICµÄÕï¶Ï¾ßÓÐÒ»¶¨µÄÒâÒå¡£¡£¡£¡£¡£ ¡£¡£±ðµÄ£¬£¬£¬ £¬£¬ £¬ÐÂѪ˨ËÄÏîÍŽá¼ì²â¿ÉÔöÌíAUC¡¢Ñ¸ËٶȺÍÓÅÊÆ±È£¬£¬£¬ £¬£¬ £¬¾ßÓиü¸ßµÄ¼ì²âЧÄÜ£¬£¬£¬ £¬£¬ £¬ÓÐÖúÓÚʵʱ¸ÉÔ¤¡£¡£¡£¡£¡£ ¡£¡£



×ÛÉÏËùÊö£¬£¬£¬ £¬£¬ £¬DIC»ù´¡¼²²¡¶àÑù£¬£¬£¬ £¬£¬ £¬ÁÙ´²·ÖÆÚÖØ´ó£¬£¬£¬ £¬£¬ £¬ÓëÆäËûѪ˨ÐÔ¼²²¡µÄÅбðÕï¶Ï½ÏÄÑÌ⣬£¬£¬ £¬£¬ £¬¼«Ò×±»ºöÊÓ£¬£¬£¬ £¬£¬ £¬Ê¹ÓÃͨÀýÄýѪָ±êÕï¶ÏDICʱ£¬£¬£¬ £¬£¬ £¬DIC»¼ÕßÍùÍùÒѾ­½øÈëÖÐÍíÆÚ£¬£¬£¬ £¬£¬ £¬´Ëʱ»¼ÕßµÄÔ¤ºóÒ»Ñùƽ³£½Ï²î£¬£¬£¬ £¬£¬ £¬ÄýѪ¡¢ÏËÈÜϵͳÔÓÂÒ£¬£¬£¬ £¬£¬ £¬ÄÑÒÔ»Ö¸´Õý³£Ë®Æ½£¬£¬£¬ £¬£¬ £¬Ò×±¬·¢¶àÆ÷¹Ù¹¦Ð§Õϰ­×ÛºÏÕ÷£¨MODS£©£¬£¬£¬ £¬£¬ £¬²¡ËÀÂʼ«¸ß¡£¡£¡£¡£¡£ ¡£¡£ÐÂѪ˨ËÄÏîTM¡¢TAT¡¢PIC¡¢t-PAICÔÚDICÔçÆÚÕï¶ÏÖоßÓÐÖ¸µ¼ÒâÒ壬£¬£¬ £¬£¬ £¬²¢ÇÒ±ÈͨÀýÄýѪָ±ê¸üÔçÌáÐÑÄýѪÓëÏËÈÜϵͳÒì³££¬£¬£¬ £¬£¬ £¬Åú×¢Æä¶ÔÔçÆÚDIC¾ßÓÐÓÅÒìµÄÕï¶Ï¼ÛÖµ¡£¡£¡£¡£¡£ ¡£¡£Í¨¹ýÐÂѪ˨ËÄÏî¼ì²â£¬£¬£¬ £¬£¬ £¬¿ÉÖúÁ¦ÁÙ´²¾«×¼ÅжÏDICµÄʱÆÚ£¬£¬£¬ £¬£¬ £¬ÌáÐÑÁÙ´²¼°Ôç¾ÙÐиÉÔ¤²¢µ÷½âÖÎÁƼƻ®¡£¡£¡£¡£¡£ ¡£¡£




×ðÁú¹Ù·½ÑªË¨ËÄÏî²úÆ·ÏÈÈÝ


? ÒªÁìѧ£º´Å΢Á£»£»£»£» £»£»¯Ñ§·¢¹â·¨

? Ñù±¾ÀàÐÍ£ºèÛéÚËáÄÆÑª½¬

? Ð£×¼ÖʿأºËæºÐÔùÓè

? ÊÊÓûúÐÍ£ºÈ«ÐÂÈý¿îÈ«×Ô¶¯»¯Ñ§·¢¹âÒÇÆ÷¡£¡£¡£¡£¡£ ¡£¡£¾ßÓÐÕ¼µØÐ¡£¬£¬£¬ £¬£¬ £¬²âÊÔËÙÂʿ죬£¬£¬ £¬£¬ £¬ÎÞаÐԸߵÈÓÅÊÆ£¬£¬£¬ £¬£¬ £¬¿ÉÒÔÖª×ã¶àÖÖÖն˿ͻ§ÐèÇ󡣡£¡£¡£¡£ ¡£¡£



²Î¿¼ÎÄÏ×

[1] ÖлªÒ½Ñ§»áѪҺѧ·Ö»áѪ˨ÓëֹѪѧ×飮ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕï¶ÏÖйúר¼Ò¹²Ê¶(2017Äê°æ)[J]. ÖлªÑªÒºÑ§ÔÓÖ¾, 2017, 38(5):361-363.

[2] ÍõÁ¦¾ü£¬£¬£¬ £¬£¬ £¬²ñÑÞ·Ò. ŧ¶¾Ö¢²¢·¢ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕïÖμ±Õïר¼Ò¹²Ê¶[J].ÊÊÓÃÄ¥Á·Ò½Ê¦ÔÓÖ¾, 2017, 03(v.9):7-10.DOI:CNKI:SUN:CJCP.0.2017-03-003.

[3] ºú×ÏÞ±,ÂíÏþ´º.ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕï¶Ï±ê×¼£ºÎÊÌâÓëÆÚÍû[J].ÖйúÊÊÓÃÄÚ¿ÆÔÓÖ¾,2021,41(06):457-461.DOI:10.19538/j.nk2021060101.

[4] Ëξ°´º,ÕÅΰ,ÕÅÀÚ,µÈ.ÖØÖ¢»¼ÕßÄýѪ¹¦Ð§Õϰ­±ê×¼»¯ÆÀ¹ÀÖйúר¼Ò¹²Ê¶[J].½â·Å¾üҽѧÔÓÖ¾,2022,47(02):107-117.

[5] ÉÛÃã,ѦÏÔ×Å,Íõ˼¼Ñ,µÈ.¼±ÐÔ³öѪÐÔÄýѪ¹¦Ð§Õϰ­ÕïÖÎר¼Ò¹²Ê¶[J].Öлª¼±ÕïҽѧÔÓ,2020,29(6):780-787.

[6] Wada H, Takahashi H, Uchiyama T, et al. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis[J]. Thrombosis Journal, 2017,15(1).

[7] Mei H, Jiang Y, Luo L, et al. Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation: A multi-center prospective observational study. Thromb Res. 2019;173:20-26.


END

ÎÄÕÂȪԴ£º×ðÁú¹Ù·½ÉúÎï

Ôð±à£ºEcho

У¶Ô£ºPretty¡¢Miss Jia


 
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿